Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription.

PubWeight™: 1.57‹?› | Rank: Top 4%

🔗 View Article (PMC 1472144)

Published in J Virol on June 01, 2006

Authors

Fang Lu1, Latasha Day, S-J Gao, Paul M Lieberman

Author Affiliations

1: The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.

Articles citing this

Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog (2010) 1.94

Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe (2010) 1.70

Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J Virol (2008) 1.62

KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood (2008) 1.52

Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology (2008) 1.41

Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology (2007) 1.38

The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol (2007) 1.36

Coordination of KSHV latent and lytic gene control by CTCF-cohesin mediated chromosome conformation. PLoS Pathog (2011) 1.16

Kaposi's sarcoma-associated herpesvirus RTA promotes degradation of the Hey1 repressor protein through the ubiquitin proteasome pathway. J Virol (2009) 1.15

Keeping it quiet: chromatin control of gammaherpesvirus latency. Nat Rev Microbiol (2013) 1.13

Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res (2010) 1.09

Cohesins repress Kaposi's sarcoma-associated herpesvirus immediate early gene transcription during latency. J Virol (2012) 1.08

Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J Virol (2010) 1.07

Oxidative stress induces reactivation of Kaposi's sarcoma-associated herpesvirus and death of primary effusion lymphoma cells. J Virol (2010) 1.05

Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol (2012) 1.05

Cell cycle control of Kaposi's sarcoma-associated herpesvirus latency transcription by CTCF-cohesin interactions. J Virol (2009) 1.03

De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists. J Virol (2007) 1.02

KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog (2009) 1.01

Role of Kaposi's sarcoma-associated herpesvirus C-terminal LANA chromosome binding in episome persistence. J Virol (2009) 0.99

A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening. J Virol (2012) 0.98

Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog (2010) 0.98

The latency-associated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J Virol (2009) 0.97

Host epigenetic modifications by oncogenic viruses. Br J Cancer (2006) 0.97

Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen. J Biol Chem (2011) 0.97

Molecular basis for oligomeric-DNA binding and episome maintenance by KSHV LANA. PLoS Pathog (2013) 0.95

The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection. J Virol (2011) 0.95

Malignant catarrhal fever induced by alcelaphine herpesvirus 1 is associated with proliferation of CD8+ T cells supporting a latent infection. PLoS One (2008) 0.95

Tiled microarray identification of novel viral transcript structures and distinct transcriptional profiles during two modes of productive murine gammaherpesvirus 68 infection. J Virol (2012) 0.95

The internal Kaposi's sarcoma-associated herpesvirus LANA regions exert a critical role on episome persistence. J Virol (2011) 0.94

Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A. J Virol (2013) 0.94

Bub1 and CENP-F can contribute to Kaposi's sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol (2010) 0.94

Herpesvirus Genome Recognition Induced Acetylation of Nuclear IFI16 Is Essential for Its Cytoplasmic Translocation, Inflammasome and IFN-β Responses. PLoS Pathog (2015) 0.93

Murine gamma-herpesvirus immortalization of fetal liver-derived B cells requires both the viral cyclin D homolog and latency-associated nuclear antigen. PLoS Pathog (2011) 0.92

The chromatin landscape of Kaposi's sarcoma-associated herpesvirus. Viruses (2013) 0.91

KSHV LANA--the master regulator of KSHV latency. Viruses (2014) 0.91

Role of chromatin during herpesvirus infections. Biochim Biophys Acta (2009) 0.91

Kaposi's sarcoma-associated herpesvirus-encoded LANA recruits topoisomerase IIβ for latent DNA replication of the terminal repeats. J Virol (2012) 0.91

Disruption of LANA in rhesus rhadinovirus generates a highly lytic recombinant virus. J Virol (2009) 0.90

Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus replication. Semin Cancer Biol (2009) 0.90

Epigenetic regulation of EBV and KSHV latency. Curr Opin Virol (2013) 0.90

Post-Translational Modifications of Kaposi's Sarcoma-Associated Herpesvirus Regulatory Proteins - SUMO and KSHV. Front Microbiol (2012) 0.89

Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency. J Virol (2014) 0.89

Phosphorylation of the chromatin binding domain of KSHV LANA. PLoS Pathog (2012) 0.88

Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2011) 0.88

Epigenetic mechanisms in virus-induced tumorigenesis. Clin Epigenetics (2011) 0.88

Histone deacetylases in herpesvirus replication and virus-stimulated host defense. Viruses (2013) 0.87

Complex alternative cytoplasmic protein isoforms of the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 generated through noncanonical translation initiation. J Virol (2012) 0.87

Influence of ND10 components on epigenetic determinants of early KSHV latency establishment. PLoS Pathog (2014) 0.86

Molecular biology of KSHV lytic reactivation. Viruses (2015) 0.86

Site-specific association with host and viral chromatin by Kaposi's sarcoma-associated herpesvirus LANA and its reversal during lytic reactivation. J Virol (2014) 0.86

Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression. Virology (2009) 0.86

Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression. J Virol (2015) 0.84

Leucine zipper domain is required for Kaposi sarcoma-associated herpesvirus (KSHV) K-bZIP protein to interact with histone deacetylase and is important for KSHV replication. J Biol Chem (2012) 0.83

Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induction by hypoxia and hypoxia-inducible factors. J Virol (2011) 0.82

Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids. J Virol (2014) 0.81

EBNA1 binding and epigenetic regulation of gastrokine tumor suppressor genes in gastric carcinoma cells. Virol J (2014) 0.79

EBNA2 Drives Formation of New Chromosome Binding Sites and Target Genes for B-Cell Master Regulatory Transcription Factors RBP-jκ and EBF1. PLoS Pathog (2016) 0.78

LANA-Mediated Recruitment of Host Polycomb Repressive Complexes onto the KSHV Genome during De Novo Infection. PLoS Pathog (2016) 0.78

KSHV Genome Replication and Maintenance. Front Microbiol (2016) 0.78

Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus. J Virol (2012) 0.78

Genome-wide histone acetylation profiling of Herpesvirus saimiri in human T cells upon induction with a histone deacetylase inhibitor. J Virol (2011) 0.78

Detection of the genome and transcripts of a persistent DNA virus in neuronal tissues by fluorescent in situ hybridization combined with immunostaining. J Vis Exp (2014) 0.78

BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency. PLoS Pathog (2017) 0.77

Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus. Infect Agent Cancer (2016) 0.77

Kaposi's Sarcoma-Associated Herpesvirus Subversion of the Anti-Inflammatory Response in Human Skin Cells Reveals Correlates of Latency and Disease Pathogenesis. J Skin Cancer (2014) 0.76

The Kaposi Sarcoma Herpesvirus Latency-associated Nuclear Antigen DNA Binding Domain Dorsal Positive Electrostatic Patch Facilitates DNA Replication and Episome Persistence. J Biol Chem (2015) 0.76

Next-Generation Sequencing in the Understanding of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Biology. Viruses (2016) 0.75

Epigenetic Landscape of Kaposi's Sarcoma-Associated Herpesvirus Genome in Classic Kaposi's Sarcoma Tissues. PLoS Pathog (2017) 0.75

Reactivation and Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus: An Update. Front Microbiol (2017) 0.75

KSHV encoded LANA recruits Nucleosome Assembly Protein NAP1L1 for regulating viral DNA replication and transcription. Sci Rep (2016) 0.75

Kaposi's Sarcoma Herpesvirus Genome Persistence. Front Microbiol (2016) 0.75

Cross-species conservation of episome maintenance provides a basis for in vivo investigation of Kaposi's sarcoma herpesvirus LANA. PLoS Pathog (2017) 0.75

Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol (2017) 0.75

KSHV and the Role of Notch Receptor Dysregulation in Disease Progression. Pathogens (2017) 0.75

MHV68 Expressing KSHV LANA Reveals Both Functional Conservation and Divergence in LANA Homologs. J Virol (2017) 0.75

Articles cited by this

Translating the histone code. Science (2001) 56.77

The language of covalent histone modifications. Nature (2000) 44.92

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell (1997) 16.79

Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11

Structure and ligand of a histone acetyltransferase bromodomain. Nature (1999) 10.08

In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood (1995) 6.91

A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76

Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science (1999) 5.55

Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology (1998) 5.43

Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J Virol (1984) 4.72

Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol (1997) 4.45

Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61

The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science (2006) 3.46

Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol (2002) 3.41

Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 3.33

The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology (1999) 3.30

Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell (1998) 3.09

Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev (2003) 2.90

Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol (2001) 2.88

KSHV and Kaposi's sarcoma: the end of the beginning? Cell (1997) 2.68

The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol (1996) 2.65

The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev (2002) 2.59

DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.41

Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol (1999) 2.36

Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol (1998) 2.34

The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol (2002) 2.32

Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol (2002) 2.28

CREB-Binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol (1999) 2.26

Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J Virol (2001) 2.25

Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J Biol Chem (2002) 2.21

Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.19

Auto-activation of the rta gene of human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus. J Gen Virol (2000) 2.17

Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol (2000) 2.17

Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. J Virol (2001) 2.13

Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer (2004) 2.00

Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. J Virol (2004) 1.98

ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol (2004) 1.97

Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. J Virol (2000) 1.96

CREB-binding protein and histone deacetylase regulate the transcriptional activity of Kaposi's sarcoma-associated herpesvirus open reading frame 50. J Virol (2001) 1.96

Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology (2000) 1.93

Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83

CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol (2003) 1.72

Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells. J Virol (2003) 1.70

Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol (2003) 1.70

Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A (2001) 1.65

Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol (2004) 1.64

Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J Virol (2005) 1.59

Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J Virol (2004) 1.57

Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J Virol (2004) 1.51

The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J Biol Chem (2001) 1.48

Latent nuclear antigen of Kaposi's sarcoma herpesvirus/human herpesvirus-8 induces and relocates RING3 to nuclear heterochromatin regions. J Gen Virol (2002) 1.34

Latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. J Virol (2006) 1.33

Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia. J Virol (2003) 1.32

Acetylated sp3 is a transcriptional activator. J Biol Chem (2003) 1.30

Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus functionally interacts with heterochromatin protein 1. J Biol Chem (2002) 1.29

KSHV LANA1 binds DNA as an oligomer and residues N-terminal to the oligomerization domain are essential for DNA binding, replication, and episome persistence. Virology (2004) 1.24

Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol (2004) 1.21

An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol (2005) 1.19

Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). Virus Res (2002) 1.17

The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Recent Results Cancer Res (2002) 1.13

Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 1.12

The KSHV latency-associated nuclear antigen: a multifunctional protein. Front Biosci (2002) 1.07

Genetic requirements for the episomal maintenance of oncogenic herpesvirus genomes. Adv Cancer Res (2002) 1.06

The terminal repeats and latency-associated nuclear antigen of herpesvirus saimiri are essential for episomal persistence of the viral genome. J Gen Virol (2002) 1.04

The latency-associated nuclear antigen of rhesus monkey rhadinovirus inhibits viral replication through repression of Orf50/Rta transcriptional activation. J Virol (2005) 1.01

The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits lytic virus replication. J Virol (2003) 0.97

DNA topoisomerase II poison TAS-103 transactivates GC-box-dependent transcription via acetylation of Sp1. J Biol Chem (2004) 0.82

Concluding overview: looking back, looking forward. Philos Trans R Soc Lond B Biol Sci (2001) 0.81

Articles by these authors

Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators. EMBO J (2008) 4.28

TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Mol Cell (2009) 2.60

The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol (2004) 2.13

Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol (2010) 1.98

ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol (2004) 1.97

Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. J Virol (2008) 1.86

Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. Mol Cell (2002) 1.76

Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol (2003) 1.70

Cell cycle regulation of chromatin at an origin of DNA replication. EMBO J (2005) 1.40

Snapshots: chromatin control of viral infection. Virology (2013) 1.39

ORC binding to TRF2 stimulates OriP replication. EMBO Rep (2006) 1.38

An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe (2012) 1.38

RNA-dependent recruitment of the origin recognition complex. EMBO J (2008) 1.37

The origin recognition complex localizes to telomere repeats and prevents telomere-circle formation. Curr Biol (2007) 1.36

Chromatin profiling of Epstein-Barr virus latency control region. J Virol (2007) 1.34

Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus. J Virol (2004) 1.33

Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment. J Virol (2009) 1.29

CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog (2010) 1.27

Telomere repeat binding factors TRF1, TRF2, and hRAP1 modulate replication of Epstein-Barr virus OriP. J Virol (2003) 1.27

Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF. J Virol (2006) 1.24

A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection. EMBO J (2012) 1.21

Epigenetic control of replication origins. Cell Cycle (2005) 1.19

Coordination of KSHV latent and lytic gene control by CTCF-cohesin mediated chromosome conformation. PLoS Pathog (2011) 1.16

Timeless preserves telomere length by promoting efficient DNA replication through human telomeres. Cell Cycle (2012) 1.16

EBV latency types adopt alternative chromatin conformations. PLoS Pathog (2011) 1.15

EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog (2011) 1.14

Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome. Proc Natl Acad Sci U S A (2013) 1.13

Chromatin organization of gammaherpesvirus latent genomes. Biochim Biophys Acta (2009) 1.12

Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt. J Virol (2010) 1.09

Cohesins repress Kaposi's sarcoma-associated herpesvirus immediate early gene transcription during latency. J Virol (2012) 1.08

Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J Virol (2005) 1.06

Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol (2012) 1.05

A redox-sensitive cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication. J Virol (2005) 1.04

Cell cycle control of Kaposi's sarcoma-associated herpesvirus latency transcription by CTCF-cohesin interactions. J Virol (2009) 1.03

Epstein-Barr virus episome stability is coupled to a delay in replication timing. J Virol (2008) 1.02

TERRA, CpG methylation and telomere heterochromatin: lessons from ICF syndrome cells. Cell Cycle (2010) 1.01

14-3-3 binding sites in the snail protein are essential for snail-mediated transcriptional repression and epithelial-mesenchymal differentiation. Cancer Res (2010) 1.01

Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs. Dev Cell (2013) 1.01

Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). Virol J (2010) 1.00

Epstein-Barr virus immediate-early protein Zta co-opts mitochondrial single-stranded DNA binding protein to promote viral and inhibit mitochondrial DNA replication. J Virol (2008) 0.96

Regulation of Epstein-Barr virus OriP replication by poly(ADP-ribose) polymerase 1. J Virol (2010) 0.96

The CBP bromodomain and nucleosome targeting are required for Zta-directed nucleosome acetylation and transcription activation. Mol Cell Biol (2003) 0.96

Polyphosphoramidate gene carriers: effect of charge group on gene transfer efficiency. Gene Ther (2004) 0.96

Molecular basis for oligomeric-DNA binding and episome maintenance by KSHV LANA. PLoS Pathog (2013) 0.95

DNA affinity purification of Epstein-Barr virus OriP-binding proteins. Methods Mol Biol (2005) 0.95

A role for MRE11, NBS1, and recombination junctions in replication and stable maintenance of EBV episomes. PLoS One (2007) 0.94

Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One (2010) 0.94

Mechanism of glycyrrhizic acid inhibition of Kaposi's sarcoma-associated herpesvirus: disruption of CTCF-cohesin-mediated RNA polymerase II pausing and sister chromatid cohesion. J Virol (2011) 0.93

Microbial fed-batch production of 1,3-propanediol by Klebsiella pneumoniae under micro-aerobic conditions. Appl Microbiol Biotechnol (2003) 0.92

CTCF binding site sequence differences are associated with unique regulatory and functional trends during embryonic stem cell differentiation. Nucleic Acids Res (2013) 0.92

Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1. J Biomol Screen (2010) 0.91

Epigenetic regulation of EBV and KSHV latency. Curr Opin Virol (2013) 0.90

CTCF regulates Kaposi's sarcoma-associated herpesvirus latency transcription by nucleosome displacement and RNA polymerase programming. J Virol (2012) 0.90

Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. J Cell Sci (2012) 0.88

Investigations of the catalytic mechanism of thioredoxin glutathione reductase from Schistosoma mansoni. Biochemistry (2011) 0.88

Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp. J Virol (2008) 0.87

Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data. Viruses (2013) 0.86

Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site. J Virol (2013) 0.85

Timeless links replication termination to mitotic kinase activation. PLoS One (2011) 0.84

The replisome pausing factor Timeless is required for episomal maintenance of latent Epstein-Barr virus. J Virol (2011) 0.84

Timeless-dependent DNA replication-coupled recombination promotes Kaposi's Sarcoma-associated herpesvirus episome maintenance and terminal repeat stability. J Virol (2013) 0.84

Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres. Cancer Biol Ther (2009) 0.84

Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Virol (2007) 0.83

Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism. Future Virol (2010) 0.82

Synthesis and biological evaluation of 1,4-naphthoquinones and quinoline-5,8-diones as antimalarial and schistosomicidal agents. Org Biomol Chem (2012) 0.81

Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication. J Virol (2010) 0.81

Bioactive activities of natural products against herpesvirus infection. J Microbiol (2013) 0.81

Regulation of Epstein-Barr virus origin of plasmid replication (OriP) by the S-phase checkpoint kinase Chk2. J Virol (2010) 0.81

Increased tumorigenicity of cells carrying recombinant human herpesvirus 8. Arch Virol (2007) 0.80

Telomeres and viruses: common themes of genome maintenance. Front Oncol (2012) 0.80

Multivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain. J Virol (2006) 0.80

Kaposi's sarcoma-associated herpesvirus virion-induced transcription activation of the ORF50 immediate-early promoter. J Virol (2005) 0.78

Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter. J Virol (2004) 0.78

Topoisomerase I and RecQL1 function in Epstein-Barr virus lytic reactivation. J Virol (2009) 0.77

Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus. ACS Chem Biol (2014) 0.77

Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening. Expert Opin Drug Discov (2010) 0.75